Sintx Technologies, Inc. (SINT)
NASDAQ: SINT · Real-Time Price · USD
2.520
-0.200 (-7.35%)
Apr 25, 2025, 9:48 AM EDT - Market open
Sintx Technologies Revenue
In the year 2024, Sintx Technologies had annual revenue of $2.89M with 9.90% growth. Sintx Technologies had revenue of $542.00K in the quarter ending December 31, 2024, a decrease of -39.91%.
Revenue (ttm)
$2.89M
Revenue Growth
+9.90%
P/S Ratio
0.70
Revenue / Employee
$144,350
Employees
20
Market Cap
6.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.89M | 260.00K | 9.90% |
| Dec 31, 2023 | 2.63M | 1.07M | 68.29% |
| Dec 31, 2022 | 1.56M | 955.00K | 157.59% |
| Dec 31, 2021 | 606.00K | 12.00K | 2.02% |
| Dec 31, 2020 | 594.00K | -95.00K | -13.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
SINT News
- 2 months ago - SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 2 months ago - SINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device Market - GlobeNewsWire
- 2 months ago - SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial - GlobeNewsWire
- 5 months ago - SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment - GlobeNewsWire
- 5 months ago - SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer - GlobeNewsWire
- 5 months ago - SINTX Technologies Announces Stock Repurchase Program - GlobeNewsWire
- 5 months ago - SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 - GlobeNewsWire
- 7 months ago - SINTX Announces Key Executive Promotions: Ryan Bock, PhD, Named Chief Technology Officer and Ann Kutsch Promoted to President of SINTX TA&T - GlobeNewsWire